127 related articles for article (PubMed ID: 26176754)
1. Economic assessment of eltrombopag in the treatment of thrombocytopenia.
Romano F; Ruggeri M; Coretti S; Giannini EG; Sacchini D; Annichiarico BE; Marchetti M; Rodeghiero F; Lidonnici D
Expert Rev Pharmacoecon Outcomes Res; 2015; 15(4):713-20. PubMed ID: 26176754
[TBL] [Abstract][Full Text] [Related]
2. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy.
Afdhal NH; Dusheiko GM; Giannini EG; Chen PJ; Han KH; Mohsin A; Rodriguez-Torres M; Rugina S; Bakulin I; Lawitz E; Shiffman ML; Tayyab GU; Poordad F; Kamel YM; Brainsky A; Geib J; Vasey SY; Patwardhan R; Campbell FM; Theodore D
Gastroenterology; 2014 Feb; 146(2):442-52.e1. PubMed ID: 24126097
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness of Eltrombopag versus Romiplostim for the Treatment of Chronic Immune Thrombocytopenia in England and Wales.
Allen R; Bryden P; Grotzinger KM; Stapelkamp C; Woods B
Value Health; 2016; 19(5):614-22. PubMed ID: 27565278
[TBL] [Abstract][Full Text] [Related]
4. Eltrombopag dose predictors in thrombocytopenic subjects with hepatitis C virus infection.
Saleh MI; Obeidat AR; Anter HA; Khanfar AA
Clin Exp Pharmacol Physiol; 2015 Oct; 42(10):1030-5. PubMed ID: 26173631
[TBL] [Abstract][Full Text] [Related]
5. Health-related quality of life in thrombocytopenic patients with chronic hepatitis C with or without cirrhosis in the ENABLE-1 and ENABLE-2 studies.
Grotzinger KM; Younossi ZM; Giannini EG; Chen PJ; Rendas-Baum R; Theodore D
Health Qual Life Outcomes; 2016 Mar; 14():49. PubMed ID: 27004952
[TBL] [Abstract][Full Text] [Related]
6. Eltrombopag: a review of its use in the treatment of thrombocytopenia in patients with chronic hepatitis C.
Burness CB
Drugs; 2014 Oct; 74(16):1961-1971. PubMed ID: 25331767
[TBL] [Abstract][Full Text] [Related]
7. Does eltrombopag really ENABLE SVR?
Leber A; Feld JJ
Gastroenterology; 2014 Feb; 146(2):339-42. PubMed ID: 24361434
[No Abstract] [Full Text] [Related]
8. Eltrombopag for thrombocytopenic patients with chronic HCV infection.
Maan R; Veldt BJ; Janssen HL
Gastroenterology; 2014 Jul; 147(1):254-5. PubMed ID: 24877871
[No Abstract] [Full Text] [Related]
9. Eltrombopag in chronic hepatitis C.
Mihăilă RG; Cipăian RC
World J Gastroenterol; 2014 Sep; 20(35):12517-21. PubMed ID: 25253952
[TBL] [Abstract][Full Text] [Related]
10. Eltrombopag for thrombocytopenic patients with hepatitis C virus infection and cirrhosis.
Ji F; Deng H; Li Z
Gastroenterology; 2014 Jul; 147(1):253-4. PubMed ID: 24877867
[No Abstract] [Full Text] [Related]
11. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C.
McHutchison JG; Dusheiko G; Shiffman ML; Rodriguez-Torres M; Sigal S; Bourliere M; Berg T; Gordon SC; Campbell FM; Theodore D; Blackman N; Jenkins J; Afdhal NH;
N Engl J Med; 2007 Nov; 357(22):2227-36. PubMed ID: 18046027
[TBL] [Abstract][Full Text] [Related]
12. [Eltrombopag for the treatment of thrombocytopenia in patients with chronic hepatitis C: two case reports].
Guglieri-López B; Ventura-Cerdá JM; Carmena-Carmena J; Climente-Mónica M
Farm Hosp; 2013; 37(5):419-21. PubMed ID: 24128106
[No Abstract] [Full Text] [Related]
13. Cost per response analysis of strategies for chronic immune thrombocytopenia.
Fust K; Parthan A; Li X; Sharma A; Zhang X; Campioni M; Lin J; Wang X; Zur R; Cetin K; Eisen M; Chandler D
Am J Manag Care; 2018 Jul; 24(8 Spec No.):SP294-SP302. PubMed ID: 30020741
[TBL] [Abstract][Full Text] [Related]
14. Bayesian Population Pharmacokinetic Modeling of Eltrombopag in Chronic Hepatitis C Patients.
Saleh MI; Melhim SB; Al-Ramadhani HM; Alzubiedi S
Eur J Drug Metab Pharmacokinet; 2019 Feb; 44(1):31-42. PubMed ID: 29948848
[TBL] [Abstract][Full Text] [Related]
15. Is treatment of moderate thrombocytopenia indicated for patients with HCV infection and cirrhosis?
Desborough MJ; Jairath V
Gastroenterology; 2014 Jul; 147(1):254. PubMed ID: 24877869
[No Abstract] [Full Text] [Related]
16. Do we have to worry for thrombocytopenia during treatment of hepatitis C.
Ince AT
Turk J Gastroenterol; 2014 Jun; 25(3):344-5. PubMed ID: 25141332
[No Abstract] [Full Text] [Related]
17. Eltrombopag (Revolade ) and thrombocytopenia in patients with hepatitis C. Hepatotoxic drug; more harms than benefits.
Prescrire Int; 2015 Sep; 24(163):208-9. PubMed ID: 26417629
[TBL] [Abstract][Full Text] [Related]
18. Modeling and simulation support eltrombopag dosing in thrombocytopenic patients with chronic HCV infection.
Zhang J; Thapar M; Farrell C; Wire MB
Pharm Res; 2015 Jun; 32(6):2015-28. PubMed ID: 25534682
[TBL] [Abstract][Full Text] [Related]
19. 12 weeks of interferon-based therapy is feasible in patients with hepatitis C-related cirrhosis and thrombocytopenia: A post hoc analysis of eltrombopag studies.
Bruno S; Sewpaul P; Russo ML; Boccaccio V; Almasio PL; Giannini EG
Dig Liver Dis; 2015 Oct; 47(10):864-8. PubMed ID: 26187555
[TBL] [Abstract][Full Text] [Related]
20. Reply: To PMID 24126097.
Afdhal NH; Theodore D
Gastroenterology; 2014 Jul; 147(1):255-6. PubMed ID: 24877870
[No Abstract] [Full Text] [Related]
[Next] [New Search]
